2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Phosphoglycerate Dehydrogenase (PHGDH)
  5. Phosphoglycerate Dehydrogenase (PHGDH) Inhibitor

Phosphoglycerate Dehydrogenase (PHGDH) Inhibitor

Phosphoglycerate Dehydrogenase (PHGDH) Inhibitors (9):

Cat. No. Product Name Effect Purity
  • HY-123269
    PKUMDL-WQ-2101
    		Inhibitor 99.94%
    PKUMDL-WQ-2101 is a non-NAD+-competing allosteric phosphoglycerate dehydrogenase (PHGDH) inhibitor with an IC50 of 34.8 μM. PKUMDL-WQ-2101 exhibits antitumor activity.
  • HY-179652
    PHGDH-IN-6
    		Inhibitor
    PHGDH-IN-6 (Compound L5) is a PHGDH allosteric inhibitor with an IC50 of 2.5 μM. PHGDH-IN-6 can be used for studying diseases related to serine synthesis.
  • HY-121970
    iGP-1
    		Inhibitor 99.43%
    iGP-1 is a cell-permeable, selective mixed inhibitor of mitochondrial sn-glycerol-3-phosphate dehydrogenase (mGPDH), with IC50s of 6.3 μM and 13.6 μM for rat mGPDH activity and H2O2 production, respectively. iGP-1 specifically blocks the mitochondrial component of the glycerophosphate shuttle without affecting cytosolic GPDH. iGP-1 not only inhibits cell proliferation and glutaminolysis, and enhances glycolysis, but also significantly alters key cellular physiological processes such as apoptosis, ROS production, HIF-1α stability and mitochondrial membrane potential. iGP-1 remains active in neutrophil cultures under both normoxic and hypoxic conditions, and serves as an ideal probe for glycerol-3-phosphate metabolic mechanisms. iGP-1 has been applied to studies on prostate cancer and related metabolic pathways.
  • HY-148570
    PHGDH-IN-3
    		Inhibitor 99.34%
    PHGDH-IN-3 is an orally active phosphoglycerate dehydrogenase (PHGDH) inhibitor. PHGDH-IN-3 inhibits PHGDH with an IC50 value of 2.8 μM. PHGDH-IN-3 can be used for the research of cancer.
  • HY-123418
    PKUMDL-WQ-2201
    		Inhibitor 98.45%
    PKUMDL-WQ-2201 is a PHGDH non-NAD+-competing allosteric inhibitor (IC50=35.7 μM). PKUMDL-WQ-2201 also inhibits PHGDH mutants with IC50s of 69 μM (T59A) and >300 μM (T56AK57A), respectively. PKUMDL-WQ-2201 inhibits de novo serine synthesis in cancer cells, and reduces tumor growth.
  • HY-161456
    PHGDH-IN-5
    		Inhibitor 98.12%
    PHGDH-IN-5 (Compound B12) is a covalen inhibitor of PHGDH with an IC50 value of 0.29 μM. PHGDH-IN-5 can inhibit cell proliferation in cancer cell lines overexpressing PHGDH. PHGDH-IN-5 can reduce the production of serine derived from glucose in MDA-MB-468 cells.
  • HY-126278
    Z1609609733
    		Inhibitor
    Z1609609733 (Compound 18) is a non-covalent 3-Phosphoglycerate dehydrogenase (PHGDH) inhibitor with an IC50 of 1.46 μM. Z1609609733 significantly inhibits serine synthesis and cancer metabolism with complete abrogation of cell proliferation.
  • HY-125273
    DNS-pE
    		Inhibitor
    DNS-pE is a 3-phosphoglycerate dehydrogenase (PHGDH) inhibitor with a Ki of 7.4 μM. DNS-pE selectively and irreversibly covalently modifies endogenous PHGDH in live mammalian cells, its vinyl sulfone moiety acts as a fluorescence quencher that becomes highly fluorescent upon covalent modification of PHGDH. DNS-pE can be used as a fluorescent dye for live-cell imaging.
  • HY-160252
    PHGDH-IN-4
    		Inhibitor
    PHGDH-IN-4 is a phosphoglycerate dehydrogenase (PHGDH) inhibitor. PHGDH-IN-4 can be used for the research of cancer.